Concepedia

Publication | Closed Access

One-year safety and tolerability profile of pridopidine in patients with Huntington disease

DOI

21

Citations

17

References

2013

Year

Ferdinando Squitieri, G. Bernhard Landwehrmeyer, Ralf Reilmann, Anne Rosser, Justo Garcı́a de Yébenes, Allan Prang, Jelena Ivkovic, Jeremy R. Bright, Åsa Rembratt
Neurology

Abstract

This study provides Class IV evidence that pridopidine (≤90 mg/day) is generally safe and well-tolerated in patients with Huntington disease for up to 1 year.

References

YearCitations

Page 1